Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has issued an update.
Shanghai Junshi Biosciences Co., Ltd. announced the acceptance of a supplemental new drug application for toripalimab, in combination with disitamab vedotin, as a first-line treatment for HER2-expressing urothelial carcinoma. This development is based on successful phase III clinical trial results, which demonstrated significant improvements in progression-free and overall survival for patients compared to traditional chemotherapy. The acceptance of this application highlights the company’s ongoing efforts to expand its treatment options and strengthen its position in the oncology market, addressing unmet clinical needs in the treatment of advanced urothelial carcinoma.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company based in China, focusing on the development and commercialization of innovative therapies. The company is known for its work in immunotherapy, particularly with its PD-1 monoclonal antibody, toripalimab, which is used to treat various types of cancer. Toripalimab has been approved for multiple indications in China and internationally, and it is included in China’s National Reimbursement Drug List for several cancer treatments.
Average Trading Volume: 11,229,306
Technical Sentiment Signal: Buy
Current Market Cap: HK$42B
Learn more about 1877 stock on TipRanks’ Stock Analysis page.